Portage Biotech Stock Z Score
| PRTG Stock | USD 3.98 0.06 1.49% |
Portage | Z Score |
Portage Biotech Company Z Score Analysis
Portage Biotech's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Portage Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Portage Biotech is extremely important. It helps to project a fair market value of Portage Stock properly, considering its historical fundamentals such as Z Score. Since Portage Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Portage Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Portage Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Portage Biotech has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Portage Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Portage Biotech's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Portage Biotech could also be used in its relative valuation, which is a method of valuing Portage Biotech by comparing valuation metrics of similar companies.Portage Biotech is currently under evaluation in z score category among its peers.
Portage Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Portage Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Portage Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Portage Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Portage Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Portage Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Portage Biotech's value.| Shares | Princeton Global Asset Management Llc | 2024-09-30 | 8.0 | The Toronto-dominion Bank | 2024-06-30 | 7.0 | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 7.0 | Qube Research & Technologies | 2024-06-30 | 4.0 | Brown Brothers Harriman & Co | 2024-06-30 | 0.0 | Sigma Planning Corp | 2024-06-30 | 0.0 | Beacon Investment Advisory Services, Inc. | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Carolinas Wealth Consulting Llc | 2024-09-30 | 0.0 | Lakeview Capital Partners, Llc | 2024-09-30 | 98.5 K | Renaissance Technologies Corp | 2024-09-30 | 10.1 K |
Portage Fundamentals
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 2.79 M | ||||
| Shares Outstanding | 1.12 M | ||||
| Shares Owned By Insiders | 29.80 % | ||||
| Shares Owned By Institutions | 17.80 % | ||||
| Number Of Shares Shorted | 10.04 K | ||||
| Price To Book | 3.19 X | ||||
| EBITDA | (18.2 M) | ||||
| Net Income | (75.34 M) | ||||
| Cash And Equivalents | 21.18 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 47 K | ||||
| Current Ratio | 11.73 X | ||||
| Book Value Per Share | 4.07 X | ||||
| Cash Flow From Operations | (14.3 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (68.17) X | ||||
| Target Price | 140.0 | ||||
| Beta | 99.48 | ||||
| Market Capitalization | 4.53 M | ||||
| Total Asset | 7.78 M | ||||
| Retained Earnings | (239.32 M) | ||||
| Working Capital | 4.82 M | ||||
| Net Asset | 7.78 M |
About Portage Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Portage Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Portage Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Portage Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out Portage Biotech Piotroski F Score and Portage Biotech Valuation analysis. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (68.17) | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.